Targeting hepatocytes with liposomal interferon-alpha: effect on metallothionein gene induction.

Interferon-alpha (INF-alpha) is the only effective drug for the treatment of chronic hepatitis B. However it can produce severe side effects during treatment. Encapsulation of INF-alpha in liposomes may reduce the side effects and enhance its therapeutic activity. We evaluated the activity of free (nonencapsulated) and liposome-encapsulated INF-alpha on in vitro cultured Chang liver cells by measuring the metallothionein gene (MT-IIA). INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG). Chang liver cells were incubated for 10 hours with 100 units/ml of free or one of the aforementioned liposomal INF-alpha formulations. We also evaluated the extended-time effects of DMPC liposomal formulations of INF-alpha and the non-encapsulated (free) INF-alpha on Chang liver cells after 12, 24 and 36 h of incubation. Total RNA was extracted and signals on Northern blots were densitometrically compared following hybridization with MT-IIA and beta actin probes. All INF-alpha formulations (free and liposomal) induced higher MT-IIA gene levels compared to non-treated control cells. Levels of MT-IIA mRNA expression were 80.9, 73.6, 43.9, and 35.3% over the control for the free, DOPE/DMPG, DMPC and DOPE/DMPC liposomal INF-alpha, respectively. The ratios of MT-IIA mRNA amounts expressed after the Chang liver cells were incubated with INF-alpha encapsulated in DMPC liposomes and the MT-IIA mRNA expressed after incubation with nonencapsulated INF-alpha are 0.7, 0.52 and 0.82 at 12, 24, and 36 hours, respectively. The results indicate that the MT-IIA mRNA level depends on the liposomal formulation of INF-alpha, and the sustained-time effect of the INF-alpha encapsulated in DMPC liposomes is parallel to that of nonencapsulated INF-alpha over a period of 36 hours.